Company NewsRegulatory SubmissionSEND
Live SEND Webinar featuring Instem’s Marc Ellison
Instem Team
The Past, Present, and Future of SEND: The Continuing Evolution of Our Nonclinical Standard
SEND Blog
Regulatory SubmissionSEND
SENDIG-GeneTox v1.0: What You Need to Know
Instem Team
Preparing your regulatory team for the new SENDIG-GeneTox requirements.
Regulatory SubmissionSENDSensible SEND
What changes can we expect for the SEND world in 2025?
Marc Ellison
Read the latest from our Sensible SEND blog.
Regulatory SubmissionSENDSensible SEND
Sensible SEND – Supporting Smart People with Smart Science
Marc Ellison
Read the latest blog from Marc Ellison, Director, SEND Solutions, Instem.
Regulatory SubmissionSEND
Meet the Experts at Instem—SEND Edition!
Mike Thurogood, CMktr
Meet Marc Ellison, Director, SEND Solutions, Instem.
Regulatory SubmissionSENDSensible SEND
Can good SEND help avoid running a carci study?
Marc Ellison
The ICH S1B guidance is making significant ripples across our industry, potentially saving years of effort in the development of a new drug, and SEND can play its part in enabling this.
Stay up to Date
Get expert tips, industry news, and fresh content delivered to your inbox.
